The estimated Net Worth of Gregory L. Verdine is at least $2.84 Миллион dollars as of 20 November 2019. Gregory Verdine owns over 30,039 units of Wave Life Sciences stock worth over $177,000 and over the last 12 years he sold WVE stock worth over $2,371,395. In addition, he makes $293,160 as Director at Wave Life Sciences.
Gregory has made over 4 trades of the Wave Life Sciences stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 30,039 units of WVE stock worth $920,095 on 20 November 2019.
The largest trade he's ever made was selling 52,000 units of Wave Life Sciences stock on 16 June 2016 worth over $868,400. On average, Gregory trades about 6,691 units every 162 days since 2013. As of 20 November 2019 he still owns at least 30,000 units of Wave Life Sciences stock.
You can see the complete history of Gregory Verdine stock trades at the bottom of the page.
Dr. Gregory L. Verdine Ph.D. serves as Director of the Company. He was our President, Chief Executive Officer and Chief Scientific Officer from our inception through December 2013 and served as Chairman of our Board from July 2013 through September 2017. Since 1989, Dr. Verdine has served as the Erving Professor of Chemistry in the Department of Stem Cell and Regenerative Biology and the Department of Chemistry and Chemical Biology at Harvard University and Harvard Medical School; he is now Erving Professor of Chemistry, Emeritus. Dr. Verdine co-founded the non-profit Gloucester Marine Genomics Institute and Gloucester Biotechnology Academy in 2013 and served as the Founding President until 2016. He is the co-founder of Fog Pharmaceuticals Inc. and currently serves as Chairman, President and CEO for the company. He is also Chairman, CEO and CSO of LifeMine Therapeutics Inc. He is also the founder of Warp Drive Bio (merged with Revolution Medicines, Inc. (Nasdaq: RVMD)) and served in various roles, from Chief Scientific Officer to Chief Executive Officer, from the company’s inception in 2012 until April 2016. Dr. Verdine founded Enanta Pharmaceuticals and served as a member of its board of directors from 1990 through its initial public offering in 2013. He is a Venture Partner at WuXi Healthcare Ventures, and has previously served as Venture Partner at AppleTree Ventures, TPG Biotech and Third Rock Ventures. He has served on the Board of Scientific Counsellors of the National Cancer Institute, and is on the Board of Scientific Consultants of the Memorial Sloan Kettering Cancer Center, and he is a Senior Advisor to Shin Nippon Biomedical Laboratories Ltd. Dr. Verdine is also the co-founder of Eleven Biotherapeutics, Tokai Therapeutics, Aileron Therapeutics, and Gloucester Pharmaceuticals (acquired by Celgene in 2010). He has also served as a director of the Chemical Biology Initiative and the Program in Cancer Chemical Biology at the Dana-Farber Cancer Institute.
As the Director of Wave Life Sciences, the total compensation of Gregory Verdine at Wave Life Sciences is $293,160. There are 7 executives at Wave Life Sciences getting paid more, with Paul Bolno having the highest compensation of $3,581,530.
Gregory Verdine is 60, he's been the Director of Wave Life Sciences since 2017. There are 2 older and 15 younger executives at Wave Life Sciences. The oldest executive at Wave Life Sciences Ltd. is Koji Miura, 71, who is the Independent Director.
Gregory's mailing address filed with the SEC is C/O WAVE LIFE SCIENCES LTD.,, 733 CONCORD AVE., CAMBRIDGE, MA, 02138.
Over the last 9 years, insiders at Wave Life Sciences have traded over $19,158,839 worth of Wave Life Sciences stock and bought 18,619,108 units worth $128,204,225 . The most active insiders traders include Plc Gsk, Capital Management, L.P.Ra ... и Capital Management, Llc Kol.... On average, Wave Life Sciences executives and independent directors trade stock every 43 days with the average trade being worth of $1,569,819. The most recent stock trade was executed by Paul Bolno on 21 August 2024, trading 48,366 units of WVE stock currently worth $279,555.
wave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded rnai.
Wave Life Sciences executives and other stock owners filed with the SEC include: